Asia Pacific Myasthenia Gravis Treatment Market Size & Outlook
Related Markets
Asia Pacific myasthenia gravis treatment market highlights
- The Asia Pacific myasthenia gravis treatment market generated a revenue of USD 367.2 million in 2024.
- The market is expected to grow at a CAGR of 6.6% from 2025 to 2045.
- In terms of segment, fcrn inhibitors was the largest revenue generating drug class in 2024.
- FcRn Inhibitors is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2025 to 2045.
Asia Pacific data book summary
| Market revenue in 2024 | USD 367.2 million |
| Market revenue in 2045 | USD 1,948.5 million |
| Growth rate | 6.6% (CAGR from 2025 to 2045) |
| Largest segment | Fcrn inhibitors |
| Fastest growing segment | FcRn Inhibitors |
| Historical data covered | 2022 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2045 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Complement Inhibitors, FcRn Inhibitors, Cholinesterase Inhibitors |
| Key market players worldwide | AstraZeneca PLC, Grifols SA Ordinary Shares - Class A, Avadel Pharmaceuticals PLC, Novartis AG ADR, Pfizer Inc, AbbVie Inc, Roche Holding AG, GlaxoSmithKline, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 11.6% of the global myasthenia gravis treatment market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2045.
- MEA is the fastest growing regional market and is projected to reach USD 271.3 million by 2045.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Myasthenia Gravis Treatment Market Scope
Myasthenia Gravis Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Avadel Pharmaceuticals PLC | View profile | 154 | 10 Earlsfort Terrace, Dublin 2, Dublin, Ireland, D02 T380 | https://www.avadel.com |
| GlaxoSmithKline | View profile | 10001+ | London, England, United Kingdom, Europe | http://www.gsk.com |
| Bausch Health Companies Inc | View profile | 20270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | https://www.bauschhealth.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Grifols SA Ordinary Shares - Class A | View profile | 23737 | Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, Spain, 08174 | https://www.grifols.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Asia Pacific myasthenia gravis treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.
Fcrn inhibitors was the largest segment with a revenue share of 76.88% in 2024. Horizon Databook has segmented the Asia Pacific myasthenia gravis treatment market based on complement inhibitors, fcrn inhibitors, cholinesterase inhibitors covering the revenue growth of each sub-segment from 2022 to 2045.
The Asia Pacific myasthenia gravis treatment market is expected to grow at the fastest rate owing to presence of a large target population in countries, such as India, China, Japan, and South Korea. In addition, growing adoption of innovative MG diagnosis techniques & treatment therapies in these countries is one of the key factors driving market growth.
Moreover, presence of local drug manufacturers and entry of leading companies in Asia Pacific countries through strategic collaborations are among factors further expected to support regional growth.
Reasons to subscribe to Asia Pacific myasthenia gravis treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific myasthenia gravis treatment market databook
-
Our clientele includes a mix of myasthenia gravis treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific myasthenia gravis treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific myasthenia gravis treatment market from 2022 to 2045, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific myasthenia gravis treatment market size, by country, 2022-2045 (US$M)
Asia Pacific Myasthenia Gravis Treatment Market Outlook Share, 2024 & 2045 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
